BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35263209)

  • 41. MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.
    Suzuki M; Tsunoda S; Koyama D; Ikeda S; Sukegawa M; Hojo H; Ohta M
    J Clin Exp Hematop; 2021 Mar; 61(1):22-28. PubMed ID: 33551437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma].
    Tian H; Chen J; Wu Y; Li LL
    Ai Zheng; 2008 Jun; 27(6):633-5. PubMed ID: 18570739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
    Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM
    Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
    Sweet K; Komrokji R; Padron E; Cubitt CL; Turner JG; Zhou J; List AF; Sallman DA; Dawson JL; Sullivan DM; Chavez J; Shah BD; Lancet JE
    Clin Cancer Res; 2020 Jan; 26(1):54-60. PubMed ID: 31636097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
    Pan J; Ghimire S; Alpdogan SO; Chapman A; Carabasi M; DiMeglio M; Gong J; Martinez-Outschoorn U; Rose L; Ramirez M; Wagner JL; Weiss M; Flomenberg N; Pro B; Porcu P; Filicko-OHara J; Gaballa S
    Leuk Lymphoma; 2021 Mar; 62(3):590-597. PubMed ID: 33146052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
    Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
    Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of Ocular Side Effects of Selinexor.
    Al-Zubidi N; Gombos DS; Hong DS; Subbiah V; Fu S; Ahnert JR; Piha-Paul SA; Tsimberidou AM; Karp DD; Bernstam FM; Naing A
    Oncologist; 2021 Jul; 26(7):619-623. PubMed ID: 33728727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
    Goldsmith SR; Liu L; Shiah K
    Curr Opin Oncol; 2022 Sep; 34(5):524-530. PubMed ID: 35880450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
    Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
    Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
    Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma].
    Li MH; Li YF; Yin QS; Mi RH; Chen L; Du JW; Wei XD
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):857-61. PubMed ID: 24171959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
    Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
    Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
    Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
    Trkulja KL; Manji F; Kuruvilla J; Laister RC
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.